Tuesday, August 12, 2025

Hepatitis

Hepatitis: Causes, Types, Symptoms, Prevention, and Global Impact

~Introduction


Hepatitis refers to inflammation of the liver, a vital organ responsible for processing nutrients, filtering toxins, and regulating many metabolic functions. This inflammation can result from various causes, including viral infections, excessive alcohol consumption, toxins, autoimmune diseases, and certain medications.

Globally, hepatitis—especially viral hepatitis—is a major public health problem. According to the World Health Organization (WHO), hundreds of millions of people are living with chronic hepatitis B and C, which together cause more deaths annually than HIV/AIDS, malaria, or tuberculosis.

~Understanding the Liver and Hepatitis

The liver plays a central role in:

  • Detoxifying harmful substances

  • Producing bile for digestion

  • Regulating blood clotting

  • Storing glycogen, vitamins, and minerals

  • Metabolizing fats, proteins, and carbohydrates

When inflammation occurs in the liver (hepatitis), these functions may be impaired, leading to symptoms ranging from mild discomfort to life-threatening complications such as liver failure or liver cancer.

~Causes of Hepatitis

Hepatitis can be classified based on its cause:

1. Viral Hepatitis

The most common cause worldwide, spread by various routes:

  • Hepatitis A virus (HAV)

  • Hepatitis B virus (HBV)

  • Hepatitis C virus (HCV)

  • Hepatitis D virus (HDV)

  • Hepatitis E virus (HEV)

2. Alcoholic Hepatitis

Caused by chronic and excessive alcohol consumption, leading to progressive liver damage.

3. Drug-Induced Hepatitis

Certain medications, herbal remedies, or toxins can trigger liver inflammation.

4. Autoimmune Hepatitis

The immune system mistakenly attacks liver cells, leading to chronic inflammation.

~Types of Viral Hepatitis

Hepatitis A (HAV)

  • Transmission: Fecal-oral route (contaminated food/water)

  • Incubation: 14–28 days

  • Course: Usually acute, self-limiting


  • Prevention: HAV vaccine, safe water, good hygiene

  • Treatment: Supportive care

Hepatitis B (HBV)

  • Transmission: Blood, sexual contact, mother-to-child

  • Incubation: 1–6 months

  • Course: Can be acute or chronic; chronic cases risk cirrhosis and liver cancer

  • Prevention: HBV vaccine, safe sex, screened blood transfusions

  • Treatment: Antiviral drugs for chronic infection (e.g., tenofovir, entecavir)

Hepatitis C (HCV)

  • Transmission: Primarily blood-to-blood contact (injections, unsafe medical procedures)

  • Incubation: 2 weeks to 6 months

  • Course: Often becomes chronic; major cause of liver transplantation

  • Prevention: No vaccine; avoid sharing needles, ensure safe medical practices

  • Treatment: Direct-acting antivirals (DAAs) can cure >95% of cases

Hepatitis D (HDV)

  • Transmission: Requires HBV for replication; spread via blood/sexual contact

  • Course: Co-infection or superinfection with HBV; more severe disease

  • Prevention: HBV vaccination indirectly prevents HDV

  • Treatment: Limited; interferon-alpha may help

Hepatitis E (HEV)

  • Transmission: Fecal-oral route, contaminated water, undercooked meat

  • Incubation: 2–10 weeks

  • Course: Acute in most; severe in pregnant women

  • Prevention: Improved sanitation, safe water

  • Treatment: Supportive; antiviral use is rare

~Symptoms of Hepatitis

Symptoms vary depending on the type and stage but may include:


Early/Acute Symptoms

  • Fatigue

  • Loss of appetite

  • Nausea and vomiting

  • Abdominal pain (especially upper right quadrant)

  • Low-grade fever

  • Joint pain

Progressive Symptoms

  • Jaundice (yellowing of skin and eyes)

  • Dark urine

  • Pale or clay-colored stools

  • Itchy skin

  • Swelling in legs and abdomen (edema, ascites in chronic cases)

~Complications

Chronic hepatitis B and C can lead to:

  • Liver fibrosis (scarring)

  • Cirrhosis (severe scarring and impaired function)

  • Liver failure

  • Hepatocellular carcinoma (primary liver cancer)

  • Portal hypertension and variceal bleeding

~Diagnosis

History and Physical Examination

  • Assess risk factors: travel, sexual history, injection drug use, transfusion history, alcohol use

  • Look for signs of jaundice, liver enlargement, or tenderness

Laboratory Tests

  • Liver Function Tests (LFTs): ALT, AST, bilirubin levels

  • Viral markers:

    • HAV IgM antibodies

    • HBsAg, anti-HBc, anti-HBs (for HBV)

    • HCV antibodies, HCV RNA

    • HDV antigen/antibodies

    • HEV IgM antibodies

  • Coagulation profile: INR/PT for liver function

  • Autoimmune markers: ANA, SMA (for autoimmune hepatitis)

Imaging

  • Ultrasound, CT, or MRI to assess liver structure

Liver Biopsy

  • In chronic hepatitis, used to stage fibrosis and assess damage

~Treatment

Treatment depends on the cause:


Acute Viral Hepatitis (A, E)

  • Supportive care

  • Hydration, nutrition

  • Avoid alcohol and hepatotoxic drugs

Chronic Hepatitis B

  • Antiviral medications: tenofovir, entecavir

  • Long-term therapy to suppress viral replication

Chronic Hepatitis C

  • Direct-acting antivirals (DAAs) for 8–12 weeks

  • Cure rates >95%

Autoimmune Hepatitis

  • Immunosuppressive drugs (prednisone, azathioprine)

Alcoholic Hepatitis

  • Complete abstinence from alcohol

  • Nutritional support

  • Corticosteroids in severe cases

~Prevention

Vaccination

  • Available for HAV and HBV (indirectly prevents HDV)

  • No vaccines yet for HCV or HEV (though HEV vaccine exists in some countries)

Safe Practices

  • Good hygiene and sanitation

  • Safe sex

  • Avoid sharing needles

  • Screen blood donations

Public Health Strategies

  • Universal HBV vaccination for newborns

  • Harm reduction programs for drug users

  • Education campaigns

~Global Impact

Epidemiology

  • Over 350 million people have chronic HBV or HCV infection.

  • HBV is most prevalent in Africa and the Western Pacific.

  • HCV is widespread, with high rates in Central Asia, Eastern Europe, and parts of Africa.

Morbidity and Mortality

  • Viral hepatitis causes over 1 million deaths annually—mostly due to chronic complications.

Economic Burden

  • Lost productivity, healthcare costs, and liver transplantation expenses strain economies.

~Hepatitis in the Context of WHO’s Elimination Goals

The WHO Global Health Sector Strategy on Viral Hepatitis (2016–2021, extended to 2030) aims to:

  • Reduce new infections by 90%

  • Reduce hepatitis-related deaths by 65%

  • Provide treatment to at least 80% of eligible people with HBV/HCV

Progress is ongoing but uneven due to gaps in diagnosis, treatment access, and public awareness.

~Conclusion

Hepatitis remains a major global health challenge. While vaccines and effective treatments exist for certain types, others—like hepatitis C—require sustained public health investment to improve testing and treatment access. Preventing hepatitis demands a combination of vaccination, public education, safe medical practices, and global cooperation.

By implementing effective prevention strategies, improving access to care, and addressing social determinants of health, the vision of eliminating hepatitis as a public health threat by 2030 can become a reality.


at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Intestinal T-Cell Lymphoma

  Intestinal T-Cell Lymphoma ~Introduction Intestinal T-cell Lymphoma is a rare and aggressive type of non-Hodgkin lymphoma that originates ...